Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796369 | 0.91 | TSHR (0.36) | POLBAPEX1HTTTDP1THRB | |
| SCHEMBL19804136 | 0.90 | CA1 (0.37) | CA1CA2FFAR1POLBAPEX1 | |
| SCHEMBL19804095 | 0.87 | CA1 (0.36) | CA1CA2FFAR1POLBAPEX1 | |
| SCHEMBL19804142 | 0.82 | CA1 (0.33) | CA1CA2FFAR1POLBAPEX1 | |
| SCHEMBL19804216 | 0.82 | CA1 (0.36) | CA1CA2FFAR1POLBAPEX1 | |
| SCHEMBL19796351 | 0.81 | CYP4A11 (0.38) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19804110 | 0.80 | GRM2 (0.35) | CA1CA2FFAR1POLBAPEX1 | |
| SCHEMBL19796322 | 0.78 | VDR (0.37) | CA1CA2POLBAPEX1HTT | |
| SCHEMBL19796365 | 0.78 | CYP4F2 (0.37) | CA1CA2FFAR1POLBAPEX1 | |
| SCHEMBL19804147 | 0.77 | TDP1 (0.40) | CA1CA2FFAR1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CA1 489/4885CA2 2120/4885FFAR1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.